JP2011519414A - 応答標的の同定及びフラビウイルス感染反応の治療に用いる組成物及び方法 - Google Patents

応答標的の同定及びフラビウイルス感染反応の治療に用いる組成物及び方法 Download PDF

Info

Publication number
JP2011519414A
JP2011519414A JP2011501777A JP2011501777A JP2011519414A JP 2011519414 A JP2011519414 A JP 2011519414A JP 2011501777 A JP2011501777 A JP 2011501777A JP 2011501777 A JP2011501777 A JP 2011501777A JP 2011519414 A JP2011519414 A JP 2011519414A
Authority
JP
Japan
Prior art keywords
clec
receptor
dlvr
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011501777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519414A5 (https=
Inventor
シエ・シエ−リアン
チ−フエイ・ウォン
シュ・ツイリン
チェン・スー−ティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2011519414A publication Critical patent/JP2011519414A/ja
Publication of JP2011519414A5 publication Critical patent/JP2011519414A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011501777A 2008-03-27 2008-05-29 応答標的の同定及びフラビウイルス感染反応の治療に用いる組成物及び方法 Ceased JP2011519414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/079,576 US7943134B2 (en) 2005-08-31 2008-03-27 Compositions and methods for identifying response targets and treating flavivirus infection responses
US12/079,576 2008-03-27
PCT/US2008/065166 WO2009120225A1 (en) 2008-03-27 2008-05-29 Compositions and methods for identifying response targets and treating flavivirus infection responses

Publications (2)

Publication Number Publication Date
JP2011519414A true JP2011519414A (ja) 2011-07-07
JP2011519414A5 JP2011519414A5 (https=) 2011-11-10

Family

ID=39722300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501777A Ceased JP2011519414A (ja) 2008-03-27 2008-05-29 応答標的の同定及びフラビウイルス感染反応の治療に用いる組成物及び方法

Country Status (9)

Country Link
US (2) US7943134B2 (https=)
EP (1) EP2257806A4 (https=)
JP (1) JP2011519414A (https=)
CN (1) CN102084250B (https=)
AU (1) AU2008353452A1 (https=)
BR (1) BRPI0822472A2 (https=)
GB (1) GB2458715A (https=)
TW (1) TWI403586B (https=)
WO (1) WO2009120225A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538119A (ja) * 2020-08-19 2023-09-06 バイトルビアエ・エル・エル・シー 感染症を診断、予防及び処置するための融合タンパク質

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488636B (zh) * 2008-02-12 2015-06-21 Academia Sinica 藥用植物霍山石斛〈dendrobium huoshanense〉多醣體及寡聚物之結構及生物活性
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014183469A1 (zh) * 2013-05-16 2014-11-20 清华大学 一种用于登革热预防和/或治疗的疫苗
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN110475873A (zh) * 2017-03-16 2019-11-19 中央研究院 诊断病毒感染的方法
US20220331349A1 (en) * 2019-01-08 2022-10-20 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to fungal infections
CN113122628B (zh) * 2019-12-30 2023-08-11 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Clec5a基因作为标志物在子宫内膜癌中诊断及治疗的应用
CN111650308B (zh) * 2020-07-13 2022-10-14 贵州中医药大学 一种金钗石斛花的hplc指纹图谱构建方法
CN113713105A (zh) * 2021-09-13 2021-11-30 中国人民解放军军事科学院军事医学研究院 用于抑制clec5a的物质在制备治疗和/或预防乙型病毒性肝炎的药物中的应用
CN115029789A (zh) * 2022-05-31 2022-09-09 南通大学 DC-SIGN的shRNA库的构建及其在原发性肝癌中的应用
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法
CN118515783B (zh) * 2024-06-06 2024-11-08 威瑞生物科技(昆明)有限责任公司 新冠病毒N蛋白和编码S1抗原mRNA分子结合的仿生病毒结构疫苗及其制备方法
CN119075281A (zh) * 2024-08-27 2024-12-06 上海瑞健未来生物科技有限公司 动静两用的间歇性高低氧训练仪、训练方法及终端

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072247A1 (en) * 2005-08-31 2007-03-29 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
WO2008133857A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
GB0112649D0 (en) 2001-05-24 2001-07-18 Isis Innovation Macrophage receptor
EP1416945A4 (en) 2001-07-17 2006-02-22 Univ Virginia IMPROVED HETEROPOLYMER COMPLEXES AND METHOD FOR THEIR USE
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
AU2003301804A1 (en) 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
CA2585719A1 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
EP1991577A2 (en) * 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072247A1 (en) * 2005-08-31 2007-03-29 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
WO2008133857A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538119A (ja) * 2020-08-19 2023-09-06 バイトルビアエ・エル・エル・シー 感染症を診断、予防及び処置するための融合タンパク質

Also Published As

Publication number Publication date
BRPI0822472A2 (pt) 2015-06-16
CN102084250B (zh) 2014-08-06
CN102084250A (zh) 2011-06-01
EP2257806A4 (en) 2011-06-15
TW201000636A (en) 2010-01-01
GB2458715A (en) 2009-09-30
TWI403586B (zh) 2013-08-01
US8460669B2 (en) 2013-06-11
WO2009120225A1 (en) 2009-10-01
EP2257806A1 (en) 2010-12-08
US20080292644A1 (en) 2008-11-27
GB0812915D0 (en) 2008-08-20
AU2008353452A1 (en) 2009-10-01
US7943134B2 (en) 2011-05-17
US20120213770A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
TWI403586B (zh) 用於偵測目標反應與治療黃病毒感染症狀之化合物及方法
US7998482B2 (en) Methods and reagents for the analysis and purification of polysaccharides
Lozach et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals
KR101523391B1 (ko) 감염 및 종양 치료를 위한 조성물 및 방법
ES2529511T3 (es) Anticuerpos monoclonales anti-claudina 1 para la inhibición de la infección por virus de la hepatitis C
JP2019503709A (ja) ヒト化抗ｃｄ７３抗体
US8425906B2 (en) Method to inhibit cancer targeting CD24
JP2017508744A (ja) 免疫応答を調節するための方法及び組成物
JP2018502123A (ja) 癌免疫療法のための組成物及び方法
JP2010521418A (ja) 悪性中皮種の治療方法
JP2010506885A (ja) Ｔｏｌｌ様受容体機能を調節するための化合物及び方法
ES3041329T3 (en) Immunomodulatory complex and uses thereof for therapy
JP5413915B2 (ja) 糖鎖認識受容体の新規用途
US9872905B2 (en) Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
TW202140571A (zh) 重組ace2-fc融合分子以及製造及使用彼等之方法
Ravlo et al. Antiviral Immunoglobulins of Chicken Egg Yolk for Potential Prevention of SARS-CoV-2 Infection. Viruses 2022, 14, 2121
US20210253732A1 (en) Antigen-binding fragment and/or aptamer for binding to an extracellular part of cd9 and therapeutic uses
WO2017151586A1 (en) Mobilizing hiv-infected cells from lymphatic reservoirs
WO2016139941A1 (ja) 抗体、フラグメント、分子及び抗ｈｃｖ治療剤
Eville I will dwell in the house of the Lord. Sacred song
JP2026012950A (ja) Ｈｔｌｖ－１細胞－感染細胞間接触感染阻害薬、ｈｔｌｖ－１感染症治療薬、ｈｔｌｖ－１関連脊髄症（ｈａｍ／ｔｓｐ）治療薬
Arevalo Dengue viral infection of endothelial cells and dengue hemorrhagic fever
JP2022523640A (ja) ウイルス組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140422

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140826